Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Vliv vitamínu B2 z tlustého střeva na střevní mikroflóru a související zdravotní biomarkery u zdravých starších dospělých

6. listopadu 2026 aktualizováno: dsm-firmenich Switzerland AG

The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

348

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Cork, Irsko
        • Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

50 let až 70 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
  2. Between 50 and 70 years of age.
  3. Has a BMI of between 18.5 - 30 Kg/m2.
  4. Participants have had a stable body weight (≤5 % change) over the past 3-months.
  5. Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
  6. Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
  7. Maintain current level of physical activity.
  8. Willing to consume the investigational product daily for the duration of the study.
  9. Female participants in menopause for at least the last one year. -

Exclusion Criteria:

  1. Are hypersensitive to any of the components of the test product.

  2. Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)

  3. Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.

  4. Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).

  5. Is a smoker or vaper.

  6. Vegetarian or vegan.

  7. Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).

  8. Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.

  9. Has a currently active eating disorder.

  10. Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.

  11. Is having a typical fibre intake >30 g fibre/day.

  12. Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.

  13. If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.

  14. Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.

  15. Has a current or history of any gastrointestinal cancer

  16. Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).

  17. Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).

  18. Have a current malignant disease or any concomitant end-stage organ disease.

  19. Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.

  20. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

  21. Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.

  22. If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).

  23. Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).

    -

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Low dose

Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Experimentální: Mid dose

Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Experimentální: high dose

Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Komparátor placeba: Placebo

One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Faecal microbial composition
Časové okno: from baseline to 12 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12

from baseline to 12 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Alpha diversity
Časové okno: from baseline to 12 weeks

Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12.

from baseline to 12 weeks
Beta diversity
Časové okno: week 0 to week 12

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12

week 0 to week 12
Faecal microbial metabolites fatty acid content at baseline and week 12
Časové okno: from baseline to 12 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12

from baseline to 12 weeks
Acetate, Propionate and Butyrate
Časové okno: baseline and week 12

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12.

baseline and week 12
Intestinal inflammation
Časové okno: from baseline to 12 weeks

Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12

from baseline to 12 weeks
Intestinal barrier integrity
Časové okno: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Oxidative stress in blood
Časové okno: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Inflammatory status in blood
Časové okno: from baseline to 12 weeks

Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12.

from baseline to 12 weeks
Gastrointestinal symptoms
Časové okno: from baseline to 12 weeks

Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12.

from baseline to 12 weeks
health-related quality of life
Časové okno: from baseline to 12 weeks

Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12.

The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase.

from baseline to 12 weeks
Stool consistency
Časové okno: from baseline to 12 weeks

Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12).

Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively.

from baseline to 12 weeks
Stool frequency
Časové okno: from baseline to 12 weeks

Stool frequency, as reported in the daily eDiary app (at baseline and week 12).

from baseline to 12 weeks
Systemic vitamin status
Časové okno: from baseline to 12 weeks

The concentration of B vitamins in blood at baseline

from baseline to 12 weeks
Faecal physiological pH and redox
Časové okno: from baseline to 12 weeks

Faecal physiological parameters measured as pH and redox potential at baseline and at week 12.

from baseline to 12 weeks
Faecal microbial composition at week 4
Časové okno: from baseline to 4 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4.

from baseline to 4 weeks
Alpha diversity at week 4
Časové okno: baseline to Week 4.

Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4.

baseline to Week 4.
Beta diversity at week 4
Časové okno: week 0 to week 4

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4

week 0 to week 4
Microbial metabolites at week 4
Časové okno: from baseline to 4 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4.

from baseline to 4 weeks
Acetate, Propionate and Butyrate at week 4
Časové okno: week 0 to week 4

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4.

week 0 to week 4

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Skin barrier integrity
Časové okno: from baseline to 12 weeks

Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12.

from baseline to 12 weeks
Skin hydration
Časové okno: from baseline to 12 weeks

Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12.

from baseline to 12 weeks
Objective skin-health
Časové okno: from baseline to 12 weeks

Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12.

from baseline to 12 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Prof Timothy Dinan, Cork University Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

12. prosince 2022

Primární dokončení (Aktuální)

6. července 2023

Dokončení studie (Aktuální)

6. července 2023

Termíny zápisu do studia

První předloženo

16. února 2023

První předloženo, které splnilo kritéria kontroly kvality

27. března 2023

První zveřejněno (Aktuální)

7. dubna 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

10. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

6. listopadu 2026

Naposledy ověřeno

1. září 2023

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit